R Is Hydrogen Or A Lower Saturated Alkyl Of Less Than Seven Carbons Patents (Class 514/629)
-
Publication number: 20110092598Abstract: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.Type: ApplicationFiled: October 7, 2008Publication date: April 21, 2011Inventors: Nandu Deorkar, James Farina, Liliana Miinea, Sameer Randive
-
Publication number: 20110092518Abstract: The present invention relates to the use of compounds which have the following general formula (I), wherein R1 and R2 are independently selected from optionally substituted aryl, optionally substituted C1 to C12 alkyl and H; and R3 and R4 are independently selected from hydroxy, optionally substituted C1 to C6 alkyl, optionally substituted phenyl and H, in a method of preventing or reducing fouling, particularly in the marine environment. The compounds of the present invention have the considerable advantage of providing the antifouling coating market with an organic alternative to the existing technology which relies heavily on the addition of copper to obtain significant antifouling effects. The compounds we have developed may be used as cheap, easy to prepare additives that do not contain metals and therefore have reduced toxicity in marine environment.Type: ApplicationFiled: May 18, 2009Publication date: April 21, 2011Applicants: NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, MARITIME AND PORT AUTHORITY OF SINGAPOREInventors: Lay Ming Serena Teo, Daniel Rittschof, Felicity Jameson, Christina Chai, Chia Lung Chen, Siew Chen Serina Lee
-
Publication number: 20110086098Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.Type: ApplicationFiled: December 16, 2010Publication date: April 14, 2011Inventors: Roger A. Rinker, Nicholas J. Casale, James H. Comly, Brenda Pollock, Atul Ayer, Johan Geerke, Martin Costello, Dennis Wieand, Kishor Parekh
-
Publication number: 20110082176Abstract: The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.Type: ApplicationFiled: October 15, 2010Publication date: April 7, 2011Inventors: Norman C.W. Wong, Joseph E.L. Tucker, Henrik C. Hansen, Fabrizio S. Chiacchia, David McCaffrey
-
Publication number: 20110076321Abstract: A self-adhesive polymer matrix which comprises a polymer that forms a gel in water, water, a sea algae extract, and a monohydric or polyhydric alcohol.Type: ApplicationFiled: September 22, 2010Publication date: March 31, 2011Applicant: BEIERSDORF AGInventors: Karl-Heinz WOELLER, Thorsten BERG, Inge KRUSE, Rainer WOLBER
-
Patent number: 7915269Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: GrantFiled: August 18, 2010Date of Patent: March 29, 2011Assignee: AR Holding Company, Inc.Inventor: Matthew W. Davis
-
Publication number: 20110070301Abstract: The present invention features a tablet including one or more pharmaceutically active agent(s), one or more thickeners, and one or more binder(s), wherein the tablet includes at least 200 mg of the pharmaceutically active agent(s) and the tablet has been fused with the binder(s) such that the tablet (i) has a water permeation time of less than 60 seconds and (ii) has an in vitro disintegration time of greater than 60 seconds.Type: ApplicationFiled: September 22, 2010Publication date: March 24, 2011Inventors: Joseph R. Luber, Harry S. Sowden, Frank J. Bunick, Leo B. Kriksunov, David W. Wynn, Christopher E. Szymczak
-
Publication number: 20110071184Abstract: The present invention features a process for making a tablet by (i) compacting a powder blend in a die to form a tablet shape, wherein the powder blend contains a pharmaceutically active agent and a meltable binder and (ii) applying radiofrequency energy to the tablet shape for a sufficient period of time to soften or melt the binder within said tablet shape to form the tablet.Type: ApplicationFiled: September 22, 2010Publication date: March 24, 2011Inventors: Frank J. Bunick, Harry S. Sowden, Joseph R. Luber, Leo B. Kriksunov, Christopher E. Szymczak
-
Publication number: 20110071185Abstract: The present invention features the present invention features a process for making a tablet by compacting a powder blend in a die platen to form a tablet shape, wherein the powder blend includes a pharmaceutically active agent and a water-containing material, and applying energy to the tablet shape for a sufficient period of time to heat the water-containing material within the tablet shape above its dehydration temperature to form the tablet.Type: ApplicationFiled: September 22, 2010Publication date: March 24, 2011Inventors: Frank J. Bunick, Harry S. Sowden, Joseph R. Luber, Leo B. Kriksunov, Christopher E. Szymczak
-
Publication number: 20110070292Abstract: Provided herein are methods for preparing liposomes and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparation contains one or more active agents. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.Type: ApplicationFiled: September 23, 2010Publication date: March 24, 2011Inventors: Indu Javeri, Kaliappanadar Nellaiappan, Bharat Dixit
-
Publication number: 20110071142Abstract: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small molecules/agents that are selectively identified for their ability to target and disrupt the transcription factor-DNA interface through unique transcription factor and/or DNA descriptors that are defined within a pharmacophore, and then testing/evaluating the candidate agents identified above through one or more in vitro assays for their ability to modulate transcription factor function including expression of this target protein and/or proteins that are downstream of the target transcription factor. The present invention also relates to various compounds described herein (e.g.Type: ApplicationFiled: March 19, 2010Publication date: March 24, 2011Applicant: BETH ISRAEL DEACONESS MEDICAL CENTERInventors: Peter Oettgen, Alan C. Rigby, Towia Libermann
-
Publication number: 20110062630Abstract: With regard to compositions derived from active ingredients and other additives in medical, food and industrial fields, there have been problems that the active ingredients cannot be uniformly mixed, and that the active ingredients become segregated and lose uniformity as the active ingredients undergo transport, input, and filling processes. There is provided a cellulose powder which improves the uniformity of compositions containing active ingredients or other additives to prevent segregation of the active ingredients, wherein the cellulose powder contains cellulose I type crystals, has an average particle diameter of less than 30 ?m, a powder density of 0.1 to 0.45 g/cm3, a tapping density of 0.1 to 0.5 g/cm3, a repose angle of 35 to 50°, a specific surface of more than or equal to 0.1 m2/g and less than 20 m2/g, an internal friction angle of 36 to 42°, and is a cellulose powder including a secondary flocculation structure in which primary particles are flocculated.Type: ApplicationFiled: May 21, 2009Publication date: March 17, 2011Applicant: ASAHI KASEI CHEMICALS CORPORATIONInventors: Yosuke Honda, Kazuhiro Oobae
-
Patent number: 7906519Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: GrantFiled: August 18, 2010Date of Patent: March 15, 2011Assignee: AR Holding Company, Inc.Inventor: Matthew W. Davis
-
Publication number: 20110059117Abstract: A liquid composition suitable for topical use comprising is provided that includes a phospholipid foaming agent and at least one solvent; and a pharmaceutically acceptable active agent; wherein the liquid composition is capable of mechanically foaming without an additional propellant; and wherein upon mechanical foaming of 250 ml of the liquid composition results in a foam with a foam volume of at least about 400 ml and a foam stability wherein at least about 50% of the foam volume is still present after about 5 minutes at 25° C., as determined using a SITA foam measurement. Also provided herein are methods of making disclosed compositions and methods of use.Type: ApplicationFiled: July 19, 2010Publication date: March 10, 2011Inventor: Bernd G. Seigfried
-
Publication number: 20110053942Abstract: The present invention relates to an orally disintegrating tablet containing (1) an active ingredient, (2) mannitol, (3) crystalline cellulose and (4) at least two kinds of particular ingredients selected from the group consisting of low-substituted hydroxypropylcellulose, cornstarch and carmellose, wherein the blending ratio of each ingredient relative to 100 wt % of the disintegrating tablet is (1) 0.01 to 50 wt %, (2) 20 to 86 wt %, (3) 10 to 30 wt %, and (4) 1 to 20 wt % for each particular ingredient and 3 to 60 wt % as the total of the particular ingredients to be blended, and an assembly of (3) crystalline cellulose to be blended has a bulk density of not more than 0.18 g/cm3, and can provide an orally disintegrating tablet having both suitable hardness and rapid disintegrability in oral cavity, which maintains orally disintegrability even under moist conditions, and hardness of not less than a predetermined level necessary for using in an automatic packaging machine.Type: ApplicationFiled: February 13, 2009Publication date: March 3, 2011Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Keiichi Fujiwara, Yasushi Ochiai, Yohei Kimura
-
Patent number: 7897645Abstract: A therapeutic agent for treatment of herpes virus-derived pain which comprises (±)-[2-[4-(3-ethoxy-2-hydroxy-propoxy) phenylcarbamoyl]ethyl]dimethylsulfonium p-toluenesulfonate represented by the formula (1) as an active ingredient.Type: GrantFiled: June 23, 2006Date of Patent: March 1, 2011Assignees: Taiho Pharmaceutical Co., Ltd., Juntendo Educational FoundationInventors: Hideoki Ogawa, Kayako Hira, Mamoru Kiniwa
-
Publication number: 20110046229Abstract: The present invention relates to controlled release drug delivery systems. In one embodiment, the present invention relates to controlled release drug delivery systems comprising a combination of at least one polyacrylic acid and at least one enteric polymer. In another embodiment, the present invention relates to a controlled release pharmaceutical composition comprising the combination of at least one active pharmaceutical ingredient and a controlled release drug delivery system, where the controlled release drug delivery system comprises the combination of at least one polyacrylic acid and at least one enteric polymer.Type: ApplicationFiled: January 22, 2009Publication date: February 24, 2011Applicant: LUBRIZOL ADVANCED MATERIALS, INC.Inventor: Elena S. Draganoiu
-
Publication number: 20110046227Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., atorvastatin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: ApplicationFiled: August 21, 2009Publication date: February 24, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew Davis
-
Publication number: 20110046120Abstract: The present disclosure provides methods and compositions for treating Impulse Control disorders including, for example, pathological gambling using ?2-adrenergic agonists, ?-adrenergic receptor antagonists, or both.Type: ApplicationFiled: October 25, 2007Publication date: February 24, 2011Inventor: Igor Elman
-
Publication number: 20110046228Abstract: Methods for safe administration of colchicine together with consumption of grapefruit juice are disclosed.Type: ApplicationFiled: August 18, 2010Publication date: February 24, 2011Applicant: MUTUAL PHARMACEUTICAL COMPANY, INC.Inventor: Matthew W. DAVIS
-
Publication number: 20110039939Abstract: The present invention concerns a liquid formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent obtainable by the following steps: (i) dissolving in a reaction vessel paracetamol in an aqueous solvent having a temperature between 65° C. and 95° C., and having pH between 5.0 and 6.0; (ii) cooling the solution so formed to a temperature equal to or above 35° C. and below 40° C. under an atmosphere of nitrogen; (iii) adding cysteine hydrochloride and sodium hydroxide simultaneously to the solution without stirring; (iv) closing the reaction vessel, and stirring the solution of step iii) in a nitrogen atmosphere. It further relates to a method for preparing the formulation.Type: ApplicationFiled: September 3, 2010Publication date: February 17, 2011Applicant: Neogen N.V.Inventor: Khaled Al Dandachi Atassi
-
Publication number: 20110039938Abstract: The present invention concerns a liquid formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent obtainable by the following steps: (i) dissolving in a reaction vessel paracetamol in an aqueous solvent having a temperature between 65° C. and 95° C., and having pH between 5.0 and 6.0; (ii) cooling the solution so formed to a temperature equal to or above 35° C. and below 40° C. under an atmosphere of nitrogen; (iii) adding cysteine hydrochloride and sodium hydroxide simultaneously to the solution without stirring; (iv) closing the reaction vessel, and stirring the solution of step iii) in a nitrogen atmosphere. It further relates to a method for preparing the formulation.Type: ApplicationFiled: June 9, 2010Publication date: February 17, 2011Applicant: Neogen N.V.Inventor: Khaled Al Dandachi Atassi
-
Publication number: 20110027352Abstract: The present invention relates to the use of a beta-adrenergic receptor agonist as active ingredient for the production of a medicament for use in the treatment of neuropathic pain, in particular neuropathic allodynia, in particular chronic neuropathic allodynia, and more generally for the production of medicaments for relieving pain. The principal field of application of the present invention is the biomedical field, and more specifically the therapeutics field. The present invention aims in particular to provide a medicament which can be used as a substitute for the antidepressants currently used to treat pain. It finds a use in the human and veterinary clinical field.Type: ApplicationFiled: January 16, 2009Publication date: February 3, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CINRSInventors: Michel Barrot, Ipek Yalcin, Marie-José Freund-Mercier, Malika Benbouzid, Nada Choucair-Jaafar
-
Publication number: 20110020440Abstract: The present invention relates to a stable pharmaceutical composition comprising soft gelatin capsules containing at least one sparingly soluble active drug (singly or in combination with sparingly soluble and/or soluble drugs) and a solvent system, wherein the solvent system comprises of solvent, co-solvent, solubilizer(s), surfactant, aqueous solution of alkali and crystal growth inhibitor. The present invention further relates to process for preparing a stable pharmaceutical composition of sparingly soluble active drug(s) in soft gelatin capsules.Type: ApplicationFiled: November 15, 2008Publication date: January 27, 2011Applicant: CADILA PHARMACEUTICALS LIMITEDInventors: Indravadan Ambalal Modi, Bakulesh Mafatlal Khamar, Ashok Sitaram Omray, Vandana Patravale, Kartik Yogesh Shah, Prashant Yogesh Patel
-
Publication number: 20110014127Abstract: Described herein are methods for effectively and accurately measuring a patient response upon administration of one or more drugs to the patient. The methods are more sensitive than current methodologies. Also described herein are compositions comprising an analgesic and a sufficient amount of an antihistamine to enhance the analgesic properties of the analgesic. With respect to these compositions, the methods described herein are useful for evaluating qualities of pain, definite improvement, and one or more bodily functions of a subject afflicted with pain. The compositions described herein are useful in improving the quality of pain in a subject or a bodily function of a subject afflicted with pain or definite improvement of a subject afflicted with pain.Type: ApplicationFiled: January 5, 2009Publication date: January 20, 2011Inventor: Bernard P. Schachtel
-
Publication number: 20110015273Abstract: The present invention refers to an parenterally administerable aqueous formulation containing paracetamol. For enhancing stability the formulation contains a sulphur containing antioxidant, preferably sodium metabisulfite. For making the formulation more soluble it contains hydroxy propyl beta cyclodextrin. The composition is used as analgesic.Type: ApplicationFiled: January 12, 2009Publication date: January 20, 2011Inventors: Rajnarayana Kandhagatla, Srihari Raju Kalidindi
-
Publication number: 20110008278Abstract: The invention is directed to a method of modulating paraptotic cell death in a cell by contacting the cell with an effective amount of a compound. selected from the group consisting of ceramide, Tumor Necrosis Factor (TNF), caspase-7, caspase-8, ?-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (RMPA), kainic acid and glutamic acid, wherein the effective amount of the compound induces paraptotic death of the cell. The invention further is directed to a method of inhibiting paraptotic cell death in a cell by contacting the cell with an effective amount of a compound selected from the group consisting of Alg-2-interacting protein 1 (AIP-1), Jun N-terminal kinase 1 (JNK1) neutralizing agent, Jun N-terminal kinase 2 (JNK2) neutralizing agent, TNF Receptor-Associated Factor 2 (TRAF2) neutralizing agent, ortho-phenanthroline and the JNK inhibitor SP 600125, wherein the effective amount of the compound inhibits paraptotic death of the cell.Type: ApplicationFiled: February 5, 2010Publication date: January 13, 2011Inventors: Sabina SPERANDIO, Dale E. Bredesen
-
Patent number: 7867523Abstract: A pharmaceutical composition for the treatment of colds and influenza. The pharmaceutical composition is a mixture of: acetaminophen, diphenhydramine, dextromethorphan, arabinogalactan, vitamin C, zinc, olive leaf extract, resveratrol and elderberry extract.Type: GrantFiled: July 18, 2008Date of Patent: January 11, 2011Inventor: Elaine A. Vanterpool
-
Publication number: 20110002985Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: August 12, 2008Publication date: January 6, 2011Applicant: ABUSE DETERRENT PHARMACEUTICAL, LLCInventors: Manish J. Shah, Ray J. Difalco
-
Publication number: 20100330006Abstract: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing skin care compositions comprising an absorption enhancer.Type: ApplicationFiled: June 30, 2010Publication date: December 30, 2010Inventor: Zahra Mansouri
-
Patent number: 7858660Abstract: Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.Type: GrantFiled: June 2, 2009Date of Patent: December 28, 2010Assignee: Adamas Pharmaceuticals, Inc.Inventors: Jack Nguyen, Gregory T. Went, Paul Spence, Timothy J. Fultz, David Chernoff, Terry L. Burkoth, Rowan Chapman, Mickey S. Urdea
-
Publication number: 20100311701Abstract: A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, O-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.Type: ApplicationFiled: June 2, 2010Publication date: December 9, 2010Applicants: Transform Pharmaceuticals, Inc, University Of South Florida, The Regents of the University Of MichiganInventors: Orn Almarsson, Magali Bourghol Hickey, Matthew Peterson, Michael J. Zaworotko, Brian Moulton, Nair Rodriguez-Hornedo
-
Publication number: 20100311830Abstract: A method of producing in a composition adapted to be applied to the mucous membranes, the physiological effects of menthol at a reduced menthol concentration, by the partial replacement of menthol by a cooling and flavour blend, including (a) at least one compound selected from the group consisting of lactoyl ethanolamide, nonanoic acid vanillyl amide and menthyl lactate; and (b) at least one compound of the Formula I in which the dotted line represents an optional single bond, the moieties R1, R2, R3, R4 and R5 being independently selected from H, CH3 and OH, three moieties being H, one CH3 and one OH, such that (i) when the optional single bond is absent, one of R1 and R5 is OH only when R3 is H; and (ii) when the optional single bond is present, R3 is CH3 and one of R1 and R5 is OH.Type: ApplicationFiled: May 20, 2010Publication date: December 9, 2010Applicant: Givaudan S.A.Inventors: Marco DE JONGE, Cornelis Winkel, Sarah Barrie Machover, Stefan Michael Furrer, Alexander P. Tondeur
-
Publication number: 20100303717Abstract: Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound.Type: ApplicationFiled: August 11, 2010Publication date: December 2, 2010Inventor: David Anderson
-
Publication number: 20100288665Abstract: A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose, sore throat, myalgia, ear pressure and fullness, and headache. The formulation further includes various excipients used in the formulation process.Type: ApplicationFiled: July 23, 2008Publication date: November 18, 2010Applicant: Kingsway Pharmaceuticals Inc.Inventor: Mark Andrew Lomaga
-
Publication number: 20100292294Abstract: The present invention concerns enhancements in the cooling effects of certain physiological coolant-containing compositions such as topically applied cosmetic, toiletry or pharmaceutical products, wherein the cooling effect of the physiological coolants is enhanced by the addition of a substance according to formula (I) or dermatologically acceptable salts thereof: R1—CR2(OR3)—CO—NR4—CR5R6—X—OR7??(I) It was found that substances represented by formula (I) are capable of bringing about greater cooling effects from reduced concentrations of physiological coolants without behaving as physiological coolants themselves, thereby enabling the preparation of compositions that do not necessarily have the characteristic minty odour of menthol-containing products and/or to allow greater freedom in creating perfumed products.Type: ApplicationFiled: March 3, 2008Publication date: November 18, 2010Applicant: GIVAUDAN NEDERLAND SERVICES B.V.Inventors: Michael Steven Watson, Stephen David Watkins, Sander Tondeur
-
Publication number: 20100286106Abstract: Treating and/or preventing prostate problems and/or metastases, by selectively occluding various groin vessels and tools for selective occluding of various groin veins, including, for example, the deferential vein. Optionally providing anti-androgen treatment after such occluding.Type: ApplicationFiled: July 13, 2008Publication date: November 11, 2010Inventors: Yigal Gat, Menachem Goren
-
Publication number: 20100286277Abstract: A method to enhance solubility of an active compound comprises combining an active compound, having an aqueous solubility that is less than or equal to about 10 mg/mL, and an amount of methoxypolyethylene glycol that is sufficient to increase the aqueous solubility of the active compound. Enhancement of aqueous solubility for this combination may be significantly greater than that of an active compound in combination with an equivalent amount of polyethylene glycol. Particularly enhanced solubility is shown where a small amount of water is also included. The invention may be used in a wide variety of applications, such as for pharmaceutical, agricultural, antimicrobial, and personal care products.Type: ApplicationFiled: January 5, 2009Publication date: November 11, 2010Inventors: David B. Wurm, David A. Wilson, Bruce A. Barner, Cynthia L. Rand, Matthew D. Miller, Michael J. Johnson
-
Publication number: 20100286204Abstract: There is provided a compound having Formula I wherein each of R1, R2, R3, R4, R5, R6, R7, R8 and R9 are independently selected from (a) H, (b) R13, —OC(R13)3, —OCH(R13)2, —OCH2R13, C(R13)3, —CH(R13)2, or —CH2R13 wherein R13 is a halogen; (c) —CN; (d) optionally substituted alkyl, (e) optionally substituted heteroalkyl; (f) optionally substituted aryl; (g) optionally substituted heteroaryl; (h) optionally substituted arylalkyl; (i) optionally substituted heteroarylalkyl; (j) hydroxy; (k) alkoxy; (l) aryloxy; (m) —SO2-alkyl; and (n) —N(R14)C(O)R15, wherein R14 and R15 are independently selected from H and hydrocarbyl, wherein the optional substituents of (d) (e) (f) (h) and (i) are selected from the group consisting of: C1-6 alkyl, halo, cyano, nitro, haloalkyl, hydroxy, C1-6 alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino, dialkylamino, sulfonyl, sulfonamido, aryl and heteroaryl; wherein n and p are independently selected from 0 and 1; X is an optional group selected from O, S, S=0Type: ApplicationFiled: November 19, 2008Publication date: November 11, 2010Applicant: Sterix LimitedInventors: Nigel Vicker, Helen Victoria Bailey, Wesley Heaton, Joanna Mary Day, Atul Purohit, Barry Victor Lloyd Potter
-
Publication number: 20100286073Abstract: The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator.Type: ApplicationFiled: October 3, 2008Publication date: November 11, 2010Inventor: Paul JENKINS
-
Publication number: 20100286100Abstract: A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient.Type: ApplicationFiled: May 11, 2009Publication date: November 11, 2010Inventors: Eric R. First, Ashish B. Patel, Guido Schmitz, Stephanie Petaway-Hickson, Hung-Huar Tong
-
Publication number: 20100284944Abstract: Disclosed are Compounds that block off-notes in consumables and methods of blocking off-notes in consumables including off-notes provided by artificial sweeteners including aspartame, Saccharin, acesulfame K (Acesulfame potassium), sucralose and cyclamate; and including stevioside, swingle extract, glyccerhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A.Type: ApplicationFiled: March 27, 2008Publication date: November 11, 2010Inventors: Ioana Maria Ungureanu, Nicole Erna Irene Brune, Jay Patrick Slack, Kimberley Gray, Christopher Todd Simons, Jenny Ellen Evans Pennimpede
-
Publication number: 20100280113Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: ApplicationFiled: July 14, 2010Publication date: November 4, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
-
Patent number: 7820681Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Type: GrantFiled: February 17, 2009Date of Patent: October 26, 2010Assignee: Mutual Pharmaceutical Company, Inc.Inventor: Matthew W. Davis
-
Patent number: 7820718Abstract: This invention provides a method for increasing apoptosis in tumor cells and a method of decreasing a size of a tumor, said methods comprising contacting the tumor cells with: a) an effective amount of at least one antitumor chemotherapeutic agent and b) an effective amount of a ceramide, sequentially or concomitantly, wherein the apoptosis induced by the combination of the antitumor chemotherapeutic agent and the ceramide is greater than the apoptosis induced by contact of the tumor cells with either the antitumor chemotherapeutic agent alone or the ceramide alone. This invention also provides a method of treating cancer in a subject which comprises a method according to either of the above-described methods. This invention provides a method for treating cancer in a subject comprising administering to the subject an effective amount of at least one antitumor chemotherapeutic agent and an effective amount of at least one ceramide, sequentially or concomitantly.Type: GrantFiled: April 7, 1999Date of Patent: October 26, 2010Assignee: Roger Williams HospitalInventors: Harold J. Wanebo, Shashikant Mehta
-
Publication number: 20100264055Abstract: A vehicle to carry a powered medication that addresses the limitations of the prior art. It includes a system and method. A powder delivery system includes a first panel and a second panel coupled together around a periphery of the panels to form a sealed void therebetween, each the panel having a width and length about equal to a standard credit card width and length, respectively; and a powder, disposed in the void, having a quantity at least about equal to an active dose of the powder; wherein a thickness of the panels with the powder disposed therebetween is not greater than about 0.1 inches and more preferably not greater than about 0.03 inches.Type: ApplicationFiled: April 20, 2009Publication date: October 21, 2010Inventor: Jordan Eisenberg
-
Publication number: 20100267697Abstract: The present teachings provide compounds of Formula (I) and pharmaceutically acceptable salts, hydrates, and esters thereof, wherein Ar, R1, R2, R3, p, and X are defined herein. The present teachings also provide processes for producing said compounds and their pharmaceutically acceptable salts, hydrates and esters, and methods of treating a pathological condition or disorder, or alleviating a symptom thereof, using said compounds including their pharmaceutically acceptable salts, hydrates and esters. The compounds can be useful in modulating ion channel activity including treating a variety of conditions associated with the abnormal modulation of one or more voltage-gated calcium channels.Type: ApplicationFiled: December 11, 2007Publication date: October 21, 2010Applicant: WyethInventors: Vincent P. Galullo, Robert Zelle, Danielle Soenen, Christopher Todd Baker, Paul Will, Hormoz Mazdiyasni, Jinsong Guo, Andrew Fensome, Jeffrey Curtis Kern, William Jay Moore, Edward George Melenski, Justin Kaplan
-
Publication number: 20100261686Abstract: The management of pain specially chronic pain often requires the use of opiate like medications which have a large number of undesirable effects, the most important one being habituation and addiction. The present invention consists of an integrated combination of medications acting through different mechanisms that are just as powerful as opiates in the management of pain without many of the undesirable side effects such as habituation and addiction.Type: ApplicationFiled: April 10, 2009Publication date: October 14, 2010Inventor: Jacques Benoit
-
Publication number: 20100260856Abstract: The present invention provides a core particle for a pharmaceutical preparation which features the requisite properties of a core particle, and which has enough chemical stability, and in which reactivity with the drug (an active pharmaceutical ingredient) is limited or prevented. More specifically, the present invention relates to a core particle wherein a film containing an active pharmaceutical ingredient can be formed on the surface thereof, and (1) the core particle comprises a pharmaceutically acceptable inorganic material, (2) the inorganic material is poorly soluble in water, and (3) pH of a solution of the inorganic material is 5 to 8.Type: ApplicationFiled: September 8, 2008Publication date: October 14, 2010Applicant: TOMITA PHARMACEUTICAL CO., LTD.Inventors: Masashi Konishi, Shouichi Oonishi, Akira Ookubo, Masashi Yunoki, Ariumi Kawamoto, Kanako Hattori
-
Publication number: 20100254939Abstract: The present invention relates to graft copolymers of polyvinyl sulfonic-co-vinyl alcohol)-g-poly(lactide-co-glycolide) (P(VS-VA)-g-PLGA) with negatively charged electrolyte properties, their method of preparation and their use. These negatively charged graft copolymers are suitable for effective loading and sustained-release of especially positively charged drugs, proteins and peptides, and drug-loaded particles from these grafted co-polymers are especially useful as parenteral or mucosal drug delivery systems for pharmaceutical applications.Type: ApplicationFiled: September 8, 2008Publication date: October 7, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas Kissel, Xiaoying Wang